Stem Cells International / 2015 / Article / Fig 2

Research Article

Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy

Figure 2

Comparison of OS in the patients of ASCT group and non-ASCT group regardless of risk stratification. The median OS was prolonged 16.7 months in ASCT group (58.8 versus 42.1 months, ).